| *Disseminated on behalf of Medicus Pharma Ltd.
Analyst Targets Paint (Nasdaq: MDCX) With Impressive Upside Potential (5 Potential Catalysts)
September 21st Greetings, Friend!
Biotech is moving fast, and only a few players are making real waves by tackling urgent health challenges with bold, inventive solutions.
One standout is pushing the boundaries with a dissolvable microneedle patch—engineered to deliver chemotherapy right where it’s needed, directly into tumors.
The aim? To change the game for skin cancer treatment, including basal cell carcinoma, with an option that’s less invasive and more patient-friendly than surgery or traditional drug regimens.
This tech is already being tested in clinical studies across the U.S. and UAE, opening the door to a fresh approach in oncology care.
At the same time, the company is widening its reach with strategic acquisitions—most recently a late-stage UK biotech developing next-gen therapies for advanced prostate disease.
These moves signal something bigger: a mission to reshape multiple treatment areas where better, safer solutions are long overdue.
Armed with deep research roots and strong industry ties, progress toward clinical and market adoption looks poised to accelerate.
With under 3Mn shares in its float, a timely acquisition just closing, and analyst targets pointing to major upside potential, this Nasdaq idea is making noise.
Worth noting—it already delivered an impressive move of approx. 28% after alert, climbing from an August 18th open of $2.10 to a $2.69 high.
If you haven’t yet, this might be the time to put this Nasdaq profile:
Take a moment to consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar.
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents.
Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX)
Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents.
Specialty: Moving innovative therapies quickly through clinical stages.
About SkinJect (Medicus Pharma's Wholly Owned Subsidiary)
Product: Patented dissolvable microneedle patch (D-MNA) for non-melanoma skin cancer, especially basal cell carcinoma.
Mechanism: Delivers doxorubicin directly to tumor via transdermal microneedles, aiming to replace invasive Mohs surgery with a painless, office-based treatment.
Rights: Exclusive global development and commercialization rights from University of Pittsburgh and Carnegie Mellon since 2016.
Clinical Progress
Phase 1 (2021): Demonstrated safety, tolerability, and some complete responses.
Phase 2: IND submitted to FDA in January 2024; patient recruitment began August 2024 at 9 US sites.
Interim analysis (March 2025): Over 60% complete clinical response; trial expanded from 60 to 90 patients.
SkinJect Value Proposition
Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors.
Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030.
Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise.
Leadership: Experienced management and board with oncology and drug development expertise.
Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones.
Find Sources Here: MDCX Presentation. MDCX Website. -----
5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark!
#1. A Low Float Scenario: With roughly 2.56Mn shares in its float, volatility potential could be heightened at the drop of a hat.
#2. Two Analyst Targets Suggest MDCX May Be Undervalued.
Take a look at this info found over at MarketBeat: | 
